The Valve Chronicles: Pressure Control Guideline Differences in Aircraft Fueling Operations Between the US & Europe

 

For this third episode in The Valve Chronicles’ look at the differences in aircraft fueling operations between the United States and Europe, the subject was pressure control and the differences in guidelines between the two geographies.

As always, to duke it out, Cla-Val’s Tom Boriack, Global Market Manager for Fueling, and Richard Hooton, Market Manager, Aviation & Ground Fueling, EMEA for Cla-Val Europe, joined host turned referee for the discussion, Tyler Kern. And, while Kern typically is the man of the podcast hour with questions, once Boriack and Hooton got going, Kern pretty much knew it was time to step back, let the sparks fly, and let these two aircraft fueling experts do their thing.

The most significant difference in discussing aircraft fueling operations between the U.S. and Europe, Boriack said, is that they operate under different standards or specifications.

“In the U.S., ATA (Air Transport Association of America, or A4A (Airlines for America), specification 103 kind of drives what our operators do both at fuel facilities and in-plane operations,” Boriack said. Similar guidelines for Europe, and in many other parts of the world, are JIG 1, issue 12.

While Boriack pointed out many of the differences in how the U.S. and Europe handle pressure control in aircraft fueling operations and how the lack of specific U.S. guidelines in some areas did leave some procedures a little unstandardized, Hooton was delighted to tout the European process.

“Because we have such a transparent procedure for pressure control, we can be in London, we can be in Geneva, we could be in Dubai, or we could be in Mumbai; it makes no difference,” Hooton said. “We are all talking about the same thing, and talking the same language, and all training the same way. And that is what is so good about the way we do it.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More